LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.

McKay, Rana R / Morgans, Alicia K / Shore, Neal D / Dunshee, Curtis / Devgan, Geeta / Agarwal, Neeraj

2024 Volume 126, Page(s) 102726

Abstract: Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains incurable and develops from biochemically recurrent PC treated with androgen deprivation therapy (ADT) following definitive therapy for localized PC, or from metastatic ... ...

Abstract	Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains incurable and develops from biochemically recurrent PC treated with androgen deprivation therapy (ADT) following definitive therapy for localized PC, or from metastatic castration-sensitive PC (mCSPC). In the mCSPC setting, treatment intensification of ADT plus androgen receptor (AR)-signaling inhibitors (ARSIs), with or without chemotherapy, improves outcomes vs ADT alone. Despite multiple phase 3 trials demonstrating a survival benefit of treatment intensification in PC, there remains high use of ADT monotherapy in real-world clinical practice. Prior studies indicate that co-inhibition of AR and poly(ADP-ribose) polymerase (PARP) may result in enhanced benefit in treating tumors regardless of alterations in DNA damage response genes involved either directly or indirectly in homologous recombination repair (HRR). Three recent phase 3 studies evaluated the combination of a PARP inhibitor (PARPi) with an ARSI as first-line treatment for mCRPC: TALAPRO-2, talazoparib plus enzalutamide; PROpel, olaparib plus abiraterone acetate and prednisone (AAP); and MAGNITUDE, niraparib plus AAP. Results from these studies have led to the recent approval in the United States of talazoparib plus enzalutamide for the treatment of mCRPC with any HRR alteration, and of both olaparib and niraparib indicated in combination with AAP for the treatment of mCRPC with BRCA alterations. Summary: Here, we review the newly approved PARPi plus ARSI treatments within the context of the mCRPC treatment landscape, provide an overview of practical considerations for the combinations in clinical practice, highlight the importance of HRR testing, and discuss the benefits of treatment intensification for patients with mCRPC.
MeSH term(s)	Humans ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/genetics ; Male ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Androgen Receptor Antagonists/therapeutic use ; Nitriles/therapeutic use ; Piperazines/therapeutic use ; Piperazines/administration & dosage ; Phthalazines/therapeutic use ; Phenylthiohydantoin/therapeutic use ; Phenylthiohydantoin/analogs & derivatives ; United States ; Receptors, Androgen/genetics ; Benzamides/therapeutic use ; Piperidines/therapeutic use ; Indazoles/therapeutic use ; Signal Transduction/drug effects ; Recombinational DNA Repair/drug effects
Chemical Substances	Poly(ADP-ribose) Polymerase Inhibitors ; Androgen Receptor Antagonists ; Nitriles ; Piperazines ; Phthalazines ; Phenylthiohydantoin (2010-15-3) ; enzalutamide (93T0T9GKNU) ; olaparib (WOH1JD9AR8) ; Receptors, Androgen ; Benzamides ; Piperidines ; Indazoles ; niraparib (HMC2H89N35) ; AR protein, human
Language	English
Publishing date	2024-03-29
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	125102-8
ISSN	1532-1967 ; 0305-7372
ISSN (online)	1532-1967
ISSN	0305-7372
DOI	10.1016/j.ctrv.2024.102726
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1022: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 611: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.

Lapuente, Maria / Conway, Dawn / Wood, Laura S / Kehoe, Kiran / Carroll Bullock, Andrea / Devgan, Geeta / Burns, Kathleen D

Clinical journal of oncology nursing

2023 Volume 27, Issue 1, Page(s) 71–80

Abstract: Background: The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of ... ...

Abstract	Background: The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy. Objectives: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting. Methods: This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment. Findings: Oncology nurses can provide comprehensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct administration, and promptly recognizing and managing immune-related adverse events.
MeSH term(s)	Humans ; Carcinoma, Transitional Cell/drug therapy ; Platinum ; Urinary Bladder Neoplasms/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use
Chemical Substances	avelumab (KXG2PJ551I) ; Platinum (49DFR088MY) ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2023-09-07
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	2014665-6
ISSN	1538-067X ; 1092-1095
ISSN (online)	1538-067X
ISSN	1092-1095
DOI	10.1188/23.CJON.71-80
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5229: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 390: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.

Wood, Laura S / Conway, Dawn / Lapuente, Maria / Salvador, George / Fernandez Gomez, Sheila / Carroll Bullock, Andrea / Devgan, Geeta / Burns, Kathleen D

Journal of infusion nursing : the official publication of the Infusion Nurses Society

2022 Volume 45, Issue 3, Page(s) 142–153

Abstract: Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 100 ... ...

Abstract	Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance is now considered the standard-of-care treatment for patients with locally advanced or metastatic UC who responded or experienced disease stabilization after 1L platinum-containing chemotherapy, and it is the only category 1 preferred checkpoint inhibitor maintenance option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for patients with cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic UC. This article reviews key considerations related to avelumab 1L maintenance therapy that infusion nurses should be familiar with, including dosing, administration, and immune-related adverse event recognition and management, to ensure safe and appropriate use of this important and impactful therapy.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Carcinoma, Transitional Cell/drug therapy ; Cisplatin/therapeutic use ; Female ; Humans ; Male ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology
Chemical Substances	Antibodies, Monoclonal, Humanized ; avelumab (KXG2PJ551I) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2022-05-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2192558-6
ISSN	1539-0667 ; 1533-1458
ISSN (online)	1539-0667
ISSN	1533-1458
DOI	10.1097/NAN.0000000000000465
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6128: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 66: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.

Reed, Mollie / Rosales, Aimee-Lauren S / Chioda, Marc D / Parker, Lindsey / Devgan, Geeta / Kettle, Jacob

Advances in therapy

2020 Volume 37, Issue 6, Page(s) 3019–3030

Abstract: Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell ... ...

Abstract	Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell lung cancer. Lorlatinib is a novel third-generation ALK TKI that is able to penetrate the blood-brain barrier and has broad-spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second-generation ALK TKIs. The safety profile of lorlatinib is distinct from those of other ALK TKIs. Adverse events are typically mild to moderate in severity, seldom result in permanent discontinuations, and are generally manageable through lorlatinib dose modifications and/or standard medical therapy. This article provides guidance to advanced practice providers (e.g., nurses, nurse practitioners, physician assistants) and oncology pharmacists for the clinical management of key lorlatinib-emergent adverse reactions (i.e., hyperlipidemias, central nervous system effects, bodyweight increase, edema, and peripheral neuropathy). As lorlatinib is both a substrate and inducer of the CYP3A enzyme system and is contraindicated with strong CYP3A inducers, relevant drug-drug interactions are also highlighted.
MeSH term(s)	Carcinoma, Non-Small-Cell Lung/drug therapy ; Consensus ; Counseling/standards ; Disease Progression ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Lactams, Macrocyclic/adverse effects ; Lactams, Macrocyclic/standards ; Lactams, Macrocyclic/therapeutic use ; Lung Neoplasms/drug therapy ; Practice Guidelines as Topic ; Protein Kinase Inhibitors/therapeutic use ; Protein-Tyrosine Kinases/therapeutic use ; Treatment Outcome
Chemical Substances	Lactams, Macrocyclic ; Protein Kinase Inhibitors ; Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2020-05-12
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	632651-1
ISSN	1865-8652 ; 0741-238X
ISSN (online)	1865-8652
ISSN	0741-238X
DOI	10.1007/s12325-020-01365-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2101: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.

Gupta, Shilpa / Costantino, Halley / Ike, Chiemeka / Gupta, Shaloo / Bhanegaonkar, Abhijeet / Su, Cathy / Thakkar, Sheena / Mackie, deMauri S / Devgan, Geeta / Katzenstein, Howard M / Liu, Frank X

The oncologist

2023 Volume 29, Issue 3, Page(s) 244–253

Abstract: Background: The treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making for first-line (1L) and first-line maintenance (1LM) treatment.: ... ...

Abstract	Background: The treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making for first-line (1L) and first-line maintenance (1LM) treatment. Materials and methods: US-based oncologists (N = 150) completed an online survey on patient demographics, practice patterns, and important factors considered in 1L/1LM selection. Multivariable logistic regression was used to assess factors associated with more vs less frequent 1L/1LM prescribing. Results: Physician reports estimated that 23% of patients with la/mUC had not received any systemic therapy in the previous 6 months; however, 46% received 1L, 32% received second-line, and 22% received subsequent-line systemic treatments. Of patients who were receiving 1L treatment, 72% were estimated to be receiving 1L platinum-based chemotherapy. Around 69% of patients eligible for 1LM received the treatment. Physicians categorized as frequent prescribers reported overall survival (OS), disease control rate (DCR), and rate of grade 3/4 adverse events (AEs) as factors associated with 1L treatment selection (all P < .05). OS, rate of grade 3/4 immune-mediated AEs, and inclusion in institutional guidelines were reported as attributes used in 1LM treatment selection (all P < .05). Multivariable analysis revealed OS, DCR, and rate of grade 3/4 AEs as important factors in oncologists' 1L treatment selection; academic practice setting and use of Response Evaluation Criteria in Solid Tumors version 1.1 were associated with 1LM use (all P < .05). Conclusion: OS and AEs were found to be relevant factors associated with offering 1L and 1LM treatment. Variability exists in physicians' decision-making in the real-world setting for la/mUC.
MeSH term(s)	Humans ; Carcinoma, Transitional Cell/drug therapy ; Urinary Bladder Neoplasms/pathology ; Response Evaluation Criteria in Solid Tumors ; Oncologists ; Physicians
Language	English
Publishing date	2023-10-16
Publishing country	England
Document type	Journal Article
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1093/oncolo/oyad267
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.

Grivas, Petros / Agarwal, Neeraj / Pal, Sumanta / Kalebasty, Arash Rezazadeh / Sridhar, Srikala S / Smith, Jodi / Devgan, Geeta / Sternberg, Cora N / Bellmunt, Joaquim

Cancer treatment reviews

2021 Volume 97, Page(s) 102187

Abstract: Although urothelial carcinoma (UC) is considered a chemotherapy-sensitive tumor, progression-free survival and overall survival (OS) are typically short following standard first-line (1L) platinum-containing chemotherapy in patients with locally advanced ...

Abstract	Although urothelial carcinoma (UC) is considered a chemotherapy-sensitive tumor, progression-free survival and overall survival (OS) are typically short following standard first-line (1L) platinum-containing chemotherapy in patients with locally advanced or metastatic disease. Immune checkpoint inhibitors (ICIs) have antitumor activity in UC and favorable safety profiles compared with chemotherapy; however, trials of 1L ICI monotherapy or chemotherapy + ICI combinations have not yet shown improved OS vs chemotherapy alone. In addition to direct cytotoxicity, chemotherapy has potential immunogenic effects, providing a rationale for assessing ICIs as switch-maintenance therapy. In the JAVELIN Bladder 100 phase 3 trial, avelumab administered as 1L maintenance with best supportive care (BSC) significantly prolonged OS vs BSC alone in patients with locally advanced or metastatic UC that had not progressed with 1L platinum-containing chemotherapy (median OS, 21.4 vs 14.3 months; hazard ratio, 0.69 [95% CI, 0.56-0.86]; P = 0.001). Efficacy benefits were seen across various subgroups, including recipients of 1L cisplatin- or carboplatin-based chemotherapy, patients with PD-L1+ or PD-L1- tumors, and patients with diverse characteristics. Results from JAVELIN Bladder 100 led to the approval of avelumab as 1L maintenance therapy for patients with locally advanced or metastatic UC that has not progressed with platinum-containing chemotherapy. Avelumab 1L maintenance is also included as a standard of care in treatment guidelines for advanced UC with level 1 evidence. This review summarizes the data that supported these developments and discusses practical considerations for administering avelumab maintenance in clinical practice, including patient selection and treatment management.
MeSH term(s)	Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Clinical Trials as Topic/statistics & numerical data ; Humans ; Maintenance Chemotherapy/methods ; Prognosis ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/secondary
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; avelumab (KXG2PJ551I)
Language	English
Publishing date	2021-03-22
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	125102-8
ISSN	1532-1967 ; 0305-7372
ISSN (online)	1532-1967
ISSN	0305-7372
DOI	10.1016/j.ctrv.2021.102187
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1022: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 611: Show issues

Order via subito

Details ▾

Article ; Online: Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.

Pujade-Lauraine, Eric / Fujiwara, Keiichi / Dychter, Samuel S / Devgan, Geeta / Monk, Bradley J

Future oncology (London, England)

2018 Volume 14, Issue 21, Page(s) 2103–2113

Abstract: Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase III trial to evaluate the role of checkpoint ...

Abstract	Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase III trial to evaluate the role of checkpoint inhibition in women with ovarian cancer. This three-arm trial is comparing avelumab administered alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory recurrent ovarian, fallopian tube or peritoneal cancer. Eligible patients are not preselected based on PD-L1 expression and may have received up to three prior lines of chemotherapy for platinum-sensitive disease, but none for resistant disease. Overall survival and progression-free survival are primary end points, and secondary end points include biomarker evaluations and pharmacokinetics.
MeSH term(s)	Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; Biomarkers ; Clinical Protocols ; Drug Resistance, Neoplasm ; Female ; Humans ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Platinum/pharmacology ; Research Design
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents, Immunological ; B7-H1 Antigen ; Biomarkers ; CD274 protein, human ; Platinum (49DFR088MY) ; avelumab (KXG2PJ551I)
Language	English
Publishing date	2018-03-27
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	2184533-5
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2018-0070
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.

George, Saby / Bell, Elizabeth J / Zheng, Ying / Kim, Ruth / White, John / Devgan, Geeta / Smith, Jodi / Lal, Lincy S / Engel-Nitz, Nicole M / Liu, Frank X

The oncologist

2021 Volume 26, Issue 7, Page(s) e1205–e1215

Abstract: Background: We investigated the association between adverse events (AEs) suspected to be immune-related and health care resource utilization, costs, and mortality among patients receiving programmed cell death 1/programmed cell death ligand 1 immune ... ...

Abstract	Background: We investigated the association between adverse events (AEs) suspected to be immune-related and health care resource utilization, costs, and mortality among patients receiving programmed cell death 1/programmed cell death ligand 1 immune checkpoint inhibitor (ICI) monotherapy for urothelial carcinoma, renal cell carcinoma, non-small cell lung cancer, or Merkel cell carcinoma. Patients and methods: We conducted a retrospective cohort study using medical and pharmacy claims and enrollment information from U.S. commercial and Medicare Advantage with Part D enrollees in the Optum Research Database from March 1, 2014, through April 30, 2019. Claims were linked with mortality data from the Social Security Death Index and the National Death Index. Eligible patients had at least one ICI claim between September 1, 2014, and April 30, 2019. Results: After adjusting for potential confounding variables, we found patients with AEs had more than double the risk of an inpatient stay (hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.9-2.5) and an 80% higher risk of an emergency visit (HR, 1.8; 95% CI, 1.6-2.1) than patients without AEs. Adjusted 6-month total costs were $24,301 higher among patients with an AE versus those without ($99,037 vs. $74,736; 95% CI, $18,828-29,774; p < .001). Mean ± SD AE-related medical costs averaged $2,359 ± $7,496 per patient per month, driven by inpatient visits, which accounted for 89.9% of AE-related costs. Adjusted risk of mortality was similar in patients with and without AEs. Conclusion: Patients with AEs had higher risks of hospitalizations, emergency room visits, and higher health care costs, driven by inpatient stays, than patients without AEs. The adjusted risk of mortality was similar between the two cohorts. Implications for practice: Patients taking immune checkpoint inhibitors (ICIs) who had adverse events (AEs) had significantly higher health care costs and utilization, driven by inpatient stays, compared with patients who did not. Given this high cost associated with AEs and the differences in the side effect profile of ICIs versus traditional chemotherapy, it is important for physicians to be cognizant of these differences when treating patients with ICIs. Ongoing evaluation, earlier recognition, and more effective, multidisciplinary management of AEs may improve patient outcomes and reduce the need for costly inpatient stays.
MeSH term(s)	Aged ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Transitional Cell ; Health Care Costs ; Humans ; Immune Checkpoint Inhibitors ; Lung Neoplasms/drug therapy ; Medicare ; Retrospective Studies ; United States ; Urinary Bladder Neoplasms
Chemical Substances	Immune Checkpoint Inhibitors
Language	English
Publishing date	2021-05-29
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1002/onco.13812
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

Bardy-Bouxin, Nathalie / Matczak, Ewa / Devgan, Geeta / Woloj, Mabel / Shapiro, Mark

Biologics : targets & therapy

2015 Volume 9, Page(s) 23–24

Language	English
Publishing date	2015-02-19
Publishing country	New Zealand
Document type	Journal Article
ISSN	1177-5475
ISSN	1177-5475
DOI	10.2147/BTT.S79507
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Effects of dose modifications on the safety and efficacy of dacomitinib for

Corral, Jesús / Mok, Tony S / Nakagawa, Kazuhiko / Rosell, Rafael / Lee, Ki Hyeong / Migliorino, Maria Rita / Pluzanski, Adam / Linke, Rolf / Devgan, Geeta / Tan, Weiwei / Quinn, Susan / Wang, Tao / Wu, Yi-Long

Future oncology (London, England)

2019 Volume 15, Issue 24, Page(s) 2795–2805

Abstract: Aim: ...

Abstract	Aim:
MeSH term(s)	Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Disease-Free Survival ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Male ; Mutation/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Quinazolinones/administration & dosage ; Quinazolinones/adverse effects
Chemical Substances	Protein Kinase Inhibitors ; Quinazolinones ; dacomitinib (5092U85G58) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
Language	English
Publishing date	2019-07-17
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2019-0299
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito